<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01115127</url>
  </required_header>
  <id_info>
    <org_study_id>Myo-Mela-2010</org_study_id>
    <nct_id>NCT01115127</nct_id>
  </id_info>
  <brief_title>Myo-inositol and Melatonin in Pre-menopausal Women</brief_title>
  <official_title>Myo-inositol and Melatonin in Menopausal Transition. A Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether myo-inositol and melatonin, or myo-inositol
      alone, or melatonin alone, are effective in normalizing irregular bleeding and anovulatory
      cycles in pre-menopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin has produced a remarkable significant improvement of thyroid function, positive
      changes of gonadotropins towards reduced levels, and in some women a re-acquisition of normal
      menstrual cycle. Furthermore, an abrogation of menopause-related depression, amelioration of
      hot-flashes and improvement of quality and duration of sleep has been reported.

      Myo-inositol is involved in several aspects of human reproduction. Elevated concentrations of
      myo-inositol in human follicular fluids appear to play a positive function in follicular
      maturity and provide a marker of good quality oocytes. Nevertheless its positive role in PCOS
      women is a consequence of a defect in the insulin signalling pathway (inositol-containing
      phosphoglycan mediators) that seems to be primarily implicated in the pathogenesis of insulin
      resistance
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum assays of thyroid hormones.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assays of gonadotropins and estradiol serum levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of metabolic markers (insulin, glucose, total cholesterol, HDL-cholesterol, triglycerides).</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of blood pressure.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of mood, hot flashes, quality of sleep.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pre-menopausal Irregular Cycles and Bleedings</condition>
  <arm_group>
    <arm_group_label>myo-inositol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin plus myo-inositol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months</description>
    <arm_group_label>melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>myo-inositol</intervention_name>
    <description>30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.</description>
    <arm_group_label>myo-inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin plus myo-inositol</intervention_name>
    <description>30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months</description>
    <arm_group_label>melatonin plus myo-inositol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all pre-menopausal women with irregular cycles and bleedings

        Exclusion Criteria:

          -  pre-menopausal women who take hormonal drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario D'Anna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Messina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Rosario D'anna</investigator_full_name>
    <investigator_title>Myo-inositol and melatonin in menopausal transition.</investigator_title>
  </responsible_party>
  <keyword>pre-menopause</keyword>
  <keyword>melatonin</keyword>
  <keyword>myo-inositol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

